F-star Therapeutics, Inc. Common Stock
FSTX
FSTX was delisted on the 8th of March, 2023.
54 hedge funds and large institutions have $35.5M invested in F-star Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 19 increasing their positions, 11 reducing their positions, and 11 closing their positions.
73% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 11
18% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 11
2% more funds holding
Funds holding: 53 → 54 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
21% less capital invested
Capital invested by funds: $45.1M → $35.5M (-$9.57M)
85% less call options, than puts
Call options by funds: $191K | Put options by funds: $1.31M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
M
Murchinson
Toronto,
Ontario, Canada
|
+$1.02M |
| 2 |
DMKJ
David M. Knott Jr
|
+$1.01M |
| 3 |
Jane Street
New York
|
+$855K |
| 4 |
Citigroup
New York
|
+$806K |
| 5 |
Russell Investments Group
London,
United Kingdom
|
+$729K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.62M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.43M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$1.35M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$574K |
FSTX Hedge Fund Activity: Q3 2022 in Review
54 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in F-star Therapeutics, Inc. Common Stock (FSTX) for Q3 2022, worth a combined $35.5M — down 21% from $45.1M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new FSTX positions and 11 closed out — a net gain of 2 holders — while 19 added to existing stakes and 11 trimmed.
The largest buyer was Murchinson, opening a new position worth an estimated $1.02M. The largest seller was Vanguard Group, cutting an estimated $3.62M.
- 54 institutional investors held F-star Therapeutics, Inc. Common Stock (FSTX) as of Q3 2022, up from 53 in Q2 2022.
- Funds reported $35.5M of F-star Therapeutics, Inc. Common Stock stock for Q3 2022, down 21% quarter-over-quarter.
- 13 funds opened new F-star Therapeutics, Inc. Common Stock positions in Q3 2022 and 11 closed out, a net change of +2 holders.
- The largest F-star Therapeutics, Inc. Common Stock buyer in Q3 2022 was Murchinson, an estimated $1.02M added.
- The largest F-star Therapeutics, Inc. Common Stock seller in Q3 2022 was Vanguard Group, an estimated $3.62M sold.
Based on aggregated 13F filings for Q3 2022.